Luna Innovations resolves litigation settlement with Hanson Medical

Dec 16 2009NewsGuard 100/100 Score

Luna Innovations Incorporated (NASDAQ:LUNA), a company focusing on sensing & instrumentation and nanotechnology, will hold a conference call with its investors relating to resolving the outstanding litigation with Hanson Medical. The settlement was announced in a press release on Friday, Dec. 11.

The live web cast will be held at 5:00 PM, ET, with Kent A. Murphy, Chairman and Chief Executive Officer, Scott Graeff, Chief Operating Officer, and Dale Messick, Chief Financial Officer. For webcast, see Luna Innovations’ website, at www.lunainnovations.com, under the tab “Investor Relations.”

Source: Luna Innovations Incorporated

Posted in: Miscellaneous News

Tags:

Comments (0)

Suggested Reading

New platform mimics immune interactions to boost cancer treatment
Researchers seek to develop noninvasive diagnostics for chronic fatigue syndrome
New DELIVER guidelines aim to accelerate nanomedicine development
Scientists overcome major challenge in gene therapy and drug delivery
Elevated cytokines found in the blood of long COVID sufferers explain heart problems
New grant aims to develop rapid biosensors for detecting African swine fever
Organoids offer new hope for safer epilepsy treatment in pregnant women
Researchers develop efficient approach for designing custom proteins

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Huntington’s disease symptoms reduced by new peptide-polymer therapy